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XRCC7Abstract Background: The human XRCC7 (MIM: 600899) is a DNA double-strand break repair
gene, involved in non-homologous end joining (NHEJ). Polymorphism G6721T (rs7003908) is
located in the intron 8 of the XRCC7. This polymorphism may regulate splicing and cause mRNA
instability.
Aim: The aim of the present study was to determine an association of G6721T XRCC7 polymor-
phism in colorectal cancer.
Subjects and methods: The study included 166 patients with colorectal cancer and 260 age and
gender frequency-matched controls. The patients and controls were Iranian (Caucasian/Muslims).
Results: Our data did not demonstrate any statistically significant association between the geno-
types of XRCC7 G6721T polymorphism and risk of colorectal cancer. There was a significant asso-
ciation between family history of cancers among their first-degree relatives (FH) and risk of
colorectal cancer (OR = 3.69, 95% CI: 2.19–6.23, P< 0.001). We further analyzed to see if the
FH influenced the association of the XRCC7 G6721T polymorphism and colorectal cancer risk.
The TT genotype among positive FH persons, remarkably increased the risk of colorectal cancer
(OR= 6.88, 95% CI: 2.27–20.8, P= 0.001).
Conclusion: The present study suggests the TT genotype of the XRCC7 G6721T polymorphism
might be a risk factor for the development of colorectal cancer among persons with positive FH.
 2016 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
DNA double-strand breaks (DSBs) may result in genetic insta-
bility and ultimately may be associated with a higher rate of
cancer development. There are two pathways for DSBs repair,
homologous recombination (HR) and non-homologous endjoining (NHEJ) pathways. In NHEJ, the broken DNA termini
are first processed to make them compatible and then sealed by
a ligation step. The NHEJ is an error-prone pathway [1].
The human X-ray cross-complementing group 7 (XRCC7;
MIM: 600899; GenBank accession no: NM_001469) is a
NHEJ repair gene, which encodes the catalytic subunit of
DNA-activated protein kinase (DNA-PKcs) [1]. DNA-PKcs
is recruited to the site of DSBs by the Ku70/Ku80 heterodimer
to form an active DNA-PK complex that is essential for the
progression of the pathway [2]. Mice with inactivated compo-
Table 1 Association between XRCC7 polymorphism and
susceptibility to colorectal cancer.
Genotypes Patients Controls OR 95% CI P-value
TT 42 73 1.0 – –
TG 84 121 1.20 0.75–1.93 0.434
GG 40 66 1.05 0.61–1.81 0.852
TG+ GG 124 187 1.15 0.74–1.79 0.529
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well as ionizing radiation hypersensitivity [3,4].
Genetic variation G6721T (rs7003908) is located in the
intron 8 of the XRCC7 gene. This polymorphism may regulate
splicing and cause mRNA instability [2]. Although NHEJ is
the major pathway for DSB repair in human cells and acts dur-
ing all phases of the cell cycle [1], only a few studies have been
reported on the association between G6721T polymorphism of
the XRCC7 gene and risk of multifactorial traits including,
several types of cancers. However the results were not consis-
tent [5–17].
Colorectal cancer is a multifactorial trait. Many genetic
variations and epigenetic modifications are involved in the
pathology of colorectal cancer [18]. To the best of our knowl-
edge, there is no report on the association between this poly-
morphism and susceptibility to colorectal cancer. Therefore
the present study was carried out.
2. Subjects and methods
2.1. Subjects
The present case-control study consisted of 166 patients (63
females, 103 males) with pathologically confirmed primary col-
orectal cancer who were recruited from chemotherapy depart-
ment of Nemazi hospital in Shiraz (south of Iran). Age and
gender frequency-matched controls (260 persons; 76 females,
184 males) were randomly selected from the healthy blood
donors. The mean age (SD; Min–Max) of the patients and
the controls were 53.0 (10.8; 21–85) and 54.0 (14.4; 15–81)
years, respectively. Control subjects had a negative history
for the diagnosis of any type of cancers. Considering that Ira-
nian population is one of the most heterogeneous populations
[19–21], we select our patients and controls from Persian (Cau-
casians) Muslims living in Fars province.
The Local Ethic Committee approved the study, and each
patient gave a written consent. The work has been carried
out in accordance with the Code of Ethics of the world Med-
ical Association (Declaration of Helsinki) for experiments in
humans.
2.2. DNA extraction and genotyping analysis
Genomic DNA was extracted from whole blood samples. The
detection of the XRCC7 G6721T (rs7003908) polymorphism
was carried out using PCR–RFLP technique, as described pre-
viously [5]. A negative control containing all reagents but
water instead of the DNA template was included in each
amplification set. Any sample with ambiguous result due to
low yield was retested and a random selection of 15% of all
samples was repeated. No discrepancies were discovered upon
replicate testing.
2.3. Statistical analysis
For the XRCC7 G6721T polymorphism, deviation of the
genotypic frequencies in the control group from those expected
under Hardy–Weinberg equilibrium was assessed using the
standard chi squared test. The genotypic-specific risks were
estimated as odds ratios (ORs) with associated 95% intervals(CIs) by unconditional logistic regression. In the analysis, the
persons with the TT genotype were assumed as reference
group.
Positive family history of cancers in first-degree relatives
(FH) is one of the strongest risk factor [22–24]. A person with
at least one first-degree relative with a kind of cancer was con-
sidered to have a positive family FH. Therefore, the partici-
pants were stratified by their FH (negative and positive) and
the data were reanalyzed. For these analyses, persons who
have negative FH were assumed as reference group. Data on
FH in the control subjects were missed for some participants.
It should be noted that among control subjects of the present
study, 11.2% had positive FH (see Section 3). In order to study
the potential effect of FH on colorectal cancer risk as well as
the risk associated with genotypes of the study polymorphism,
the ‘‘sensitivity analysis” was used. For this analysis we tested
two assumptions for the missing data: all the missed data had
negative FH (assumption I); and alternatively, 25% of them
had positive (and 75% had negative) FH (assumption II).
Statistical analysis was performed using the Statistical
Package for Social Sciences (SPSS Inc., Chicago, IL, USA)
(version 11.5). A probability of P< 0.05 was considered sta-
tistically significant. All P values were two-tailed.
3. Results and discussion
The control and patient groups were initially divided into two
gender groups. Since no statistical differences were observed
between genders for the frequencies of genotypes of XRCC7
G6721T polymorphism, the gender groups were pooled (for
control group: v2 = 1.27, df = 2, P= 0.530; for patient
group: v2 = 1.54, df = 2, P= 0.463).
Table 1 shows the genotypic distribution of the XRCC7
G6721T polymorphism between the patients and their con-
trols. The observed genotypic frequency in the control group
was in agreement with Hardy–Weinberg equilibrium
(v2 = 1.22, df = 1, P= 0.268). As shown in Table 1, our data
did not demonstrate any statistically significant association
between the genotypes and risk of colorectal cancer (for TG
vs. TT: OR= 1.20, 95% CI: 0.75–1.93, P= 0.434; for GG
vs. TT: OR = 1.05, 95% CI: 0.61–1.81, P= 0.582).
A few association studies have been published which inves-
tigated the relationship between XRCC7 G6721T polymor-
phism and risk of cancers (such as bladder cancer, prostate
cancer and renal cell carcinoma) [5–14]. The majority of these
studies found no association between this polymorphism and
risk of cancers, which is very similar to our finding.
Several studies revealed that positive FH is one of the stron-
gest risk factors for cancers [22–24]. The prevalence of positive
FH among controls and patients were 11.2% and 31.9%,
Table 2 Association between XRCC7 polymorphism and risk of colorectal cancer after stratification of participants according to
family history of cancers in their first-degree relatives.
Genotypes Family history Patients (n) Control (n) OR 95% CI P
TT Negative 27 62 1.0 – –
TT Positive 15 5 6.88 2.27–20.8 0.001
TG+GG Negative 86 143 1.0 – –
TG+GG Positive 38 21 3.01 1.65–5.46 <0.001
Table 3 Sensitivity analysis for association between XRCC7 polymorphism and risk of colorectal cancer under our two assumptions
for missing data in control group.
Genotypes Family history Assumption I Assumption II
OR 95% CI P-value OR 95% CI P-value
TT Negative 1.0 – – 1.0 – –
TT Positive 7.55 2.50–22.8 <0.001 6.20 2.17–17.6 0.001
TG+GG Negative 1.0 – – 1.0 – –
TG+GG Positive 3.49 1.93–6.32 <0.001 2.61 1.49–4.57 0.001
Notes: under assumption I and assumption II we assumed that all the missed data had negative family history; and 25% of them had positive
(and 75% had negative) family history, respectively.
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between FH and risk of colorectal cancer (OR = 3.69, 95%
CI: 2.19–6.23, P< 0.001). We further analyzed to see if FH
influenced the association of the polymorphism and colorectal
cancer risk (Table 2). The TT genotype among positive FH
persons, remarkably increased the risk of colorectal cancer
(OR = 6.88, 95% CI: 2.27–20.8, P= 0.001). In the
TG + GG genotypes, the risk of colorectal cancer increased
3.01-fold among positive FH persons (Table 2), which it is very
similar to the estimated risk of positive FH (OR= 3.69).
Taken together, it seems that these genotypes did not alter
the risk of colorectal cancer.
It should be noted that the main finding of the present
study has some limitations. Data on the FH missed for 29 par-
ticipants in control group. In order to show that the observed
associations did not occur due to the maldistribution of the
genotypes among missing data, sensitivity analysis was per-
formed. Sensitivity test was carried out under our two assump-
tions as mentioned in Section 2.3. Table 3 shows the results of
statistical analysis under our assumptions. We found that our
main finding is not a false finding due to maldistribution of
missing data. Taken together, the TT genotype among positive
FH persons remarkably increased the risk of colorectal cancer.
Very recently, similar to our present finding, it is reported that
polymorphisms of the XRCC4 and XRCC5 might be risk fac-
tors for gastric cancer development especially among persons
with positive FH [25]. Also it has been reported that XRCC7
G6721T polymorphism had no effect on hepatocellular carci-
noma risk to the whole population, but had a protective effect
on HCC risk among males and alcohol drinkers [17].
Although the functional relevance of the XRCC7 polymor-
phism is unknown, several lines of evidence suggest that our
finding is biologically plausible. The XRCC7 gene is located
on chromosome 8q11 and encodes the DNA-PKcs, which
plays a key role in NHEJ pathway for DSBs [26]. It has been
suggested that human chromosome 8q11 functionally correctsthe hyper-radiosensitivity and variable (diversity) joining
region recombination in severe combined immunodeficiency
cells and complements the DSBs repair deficiency of severe
combined immunodeficiency cells that are phenotypically sen-
sitive to radiation-induced chromosome aberration [26–28].
Although the functional significance of the G6721T XRCC7
polymorphism is unknown, this intronic genetic variation
might regulate splicing and cause mRNA instability [2] or
may be a haplotype with other genetic changes in other
disease-related genes through a linkage disequilibrium mecha-
nism [29]. However, these possibilities should be investigated in
future studies.
It has been reported that there is significant difference
between ethnicity and susceptibility to cancers in relation to
other polymorphisms [30–32]. Therefore, larger studies with
detailed data on environmental exposure from different ethnic
groups are needed to verify this initial finding.Conflict of interest
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